New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Would you offer TPO-RAs to a steroid-refractory chronic ITP patient with history of stroke?

2
1 Answers

Mednet MemberInvited Expert
Hematology · Beth Israel Deaconess Medical Center

Yes, if needed, though with a bit of trepidation, and it probably wouldn't be my first choice. Second-line chronic ITP treatment can include TPO-RA, rituximab, or splenectomy, and no one treatment is clearly better than the others (Neunert et al., PMID 31794604). Both splenectomy and TPO-RAs have in...

What treatment considerations do you make for elderly patients with relapsed/refractory follicular lymphoma?

1
2 Answers

Mednet MemberInvited Expert
Medical Oncology · City of Hope

Treatment options for R/R FL patients depend not only on the condition of the patient but what was received in 1st line and the duration of that line of therapy. Given that if a patient has received chemo-immunotherapy in the frontline setting and had a prolonged remission (> 5 years), then these ag...

What treatment do you recommend for marginal zone lymphoma in a patient who previously received bendamustine and rituximab for MALT?

1 Answers

Mednet Member
Medical Oncology · CompHealth

RCHOP or a BITE; I would use cladribine + GAZYVA with curative intent.

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How would you manage a patient with polycythemia and MPN symptoms (aquagenic pruritus, fatigue) that is JAK2/CALR/MPL negative but peripheral blood NGS positive for IDH2?

1 Answers

Mednet MemberInvited Expert
Hematology · University of Chicago

I would approach this through the framing of a polycythemia/erythrocytosis workup and then consider MPN-related interventions if a diagnosis is made! This is an excellent review that provides an overview of erythrocytosis investigation (Noumani et al., PMID 38695361). In brief, I would be thinking a...

How do you approach prophylactic antibiotics in patients who continue to have recurrent neutropenic fever following chemotherapy for solid tumors despite chemotherapy dose reduction and growth factor support?

2 Answers

Mednet MemberInvited Expert
Infectious Disease · Johns Hopkins University

This has to be individualized to the patient. It depends on the length of neutropenia, previous infections, and local antibiotic resistance. If the patient develops neutropenic fever after every cycle of chemotherapy and no obvious nidus of infection has been identified, a trial of a fluoroquinolone...

In older male patients with a history of underlying autoimmune disease, what clinical manifestations would prompt you to evaluate for VEXAS Syndrome? 

5
1 Answers

Mednet MemberInvited Expert
Rheumatology · University of Maryland School of Medicine

Hello!!!Skin lesions, elevated MCV, elevated inflammatory markers.

How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?

1 Answers

Mednet Member
Medical Oncology · Memorial Sloan Kettering

For those who relapse after first line therapy, treatment recommendations are dependent on the timing of relapse. For those who relapse within 12 months of completing first-line therapy and are fit, I would strongly consider referral to a center with CAR T-cell capabilities. As noted before, 5-year ...

Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?

2
2 Answers

Mednet Member
Radiation Oncology · Mayo Clinic

Before answering this important question, I think that we, as Radiation Oncologists, should give serious consideration to moving past the terminology of "bridging radiation therapy" and instead refer to it as "pre-CAR-T infusion radiation therapy." Bridging therapy was initially an apt name; we were...

In addition to monitoring hemoglobin and supplementing folic acid, what is your approach to hereditary spherocytosis in pregnancy?

1 Answers

Mednet MemberInvited Expert
Hematology · University of Maryland

I use the same transfusion threshold for the general pregnant population but I do refer to maternofetal medicine/high risk pregnancy clinic for closer fetal monitoring. My personal preference is to obtain genetic testing to confirm the specific mutation responsible for hereditary spherocytosis as it...

How do you manage B12 deficiency refractory to subcutaneous replacement?

2 Answers

Mednet MemberInvited Expert
Hematology · Gundersen Health

I tend to start with IM injections of B12 when patients are severely deficient. The most common mistake in replacing severely low B12 is to not load, or to check levels too early. I have not used SQ administration before. It should absorb, but if you are having issues I would go to IM and start week...